在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human Serine/threonine-protein kinase B-raf(BRAF) ELISA kit

  • 中文名稱:
    人絲氨酸/蘇氨酸蛋白激酶B-raf(BRAF)酶聯免疫試劑盒
  • 貨號:
    CSB-EL002791HU
  • 規格:
    96T/48T
  • 價格:
    ¥3600/¥2500
  • 其他:

產品詳情

  • 產品描述:
    人絲氨酸/蘇氨酸蛋白激酶B-raf(BRAF)酶聯免疫試劑盒(CSB-EL002791HU)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、細胞裂解物樣本中的BRAF含量。BRAF是一種原癌基因,其編碼的蛋白在MAPK信號通路中發揮關鍵作用。該通路參與細胞生長、增殖和存活等過程。BRAF突變可使通路持續激活,導致腫瘤發生。目前針對BRAF靶點已開展大量研究,開發出多種靶向藥物用于癌癥治療。試劑盒檢測范圍為31.25 pg/mL-2000 pg/mL,該產品適用于體外研究BRAF在腫瘤發生機制、信號通路調控或藥物干預實驗中的表達水平變化,為癌癥相關基礎研究、分子靶點篩選及生物標志物探索提供可靠工具。本品僅用于科研,不用于臨床診斷,產品具體參數及操作步驟詳見產品說明書。
  • 別名:
    FLJ95109 ELISA Kit; 94 kDa B raf protein ELISA Kit; B raf 1 ELISA Kit; B raf ELISA Kit; B Raf proto oncogene serine threonine protein kinase ELISA Kit; B Raf proto oncogene; serine/threonine kinase ELISA Kit; B RAF1 ELISA Kit; B-Raf proto-oncogene serine/threonine-protein kinase (p94) ELISA Kit; BRAF 1 ELISA Kit; BRAF ELISA Kit; BRAF_HUMAN ELISA Kit; BRAF1 ELISA Kit; cRmil ELISA Kit; MGC126806 ELISA Kit; MGC138284 ELISA Kit; Murine sarcoma viral (v-raf) oncogene homolog B1 ELISA Kit; Murine sarcoma viral v raf oncogene homolog B1 ELISA Kit; NS7 ELISA Kit; Oncogen BRAF ELISA Kit; oncogene BRAF1 ELISA Kit; p94 ELISA Kit; Proto-oncogene B-Raf ELISA Kit; Proto-oncogene c-Rmil ELISA Kit; RAFB 1 ELISA Kit; RAFB1 ELISA Kit; RMIL ELISA Kit; Serine/threonine-protein kinase B-raf ELISA Kit; v raf murine sarcoma viral oncogene homolog B ELISA Kit; v raf murine sarcoma viral oncogene homolog B1 ELISA Kit; v-Raf murine sarcoma viral oncogene homolog B1 ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, cell lysates
  • 檢測范圍:
    31.25 pg/mL-2000 pg/mL
  • 靈敏度:
    7.8 pg/mL
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Cell Biology
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度:
    To assess the linearity of the assay, samples were spiked with high concentrations of human BRAF in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
     SampleSerum(n=4)
    1:1Average %90
    Range %80-100
    1:2Average %97
    Range %91-105
    1:4Average %99
    Range %92-110
    1:8Average %92
    Range %86-98
  • 回收率:
    The recovery of human BRAF spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9589-104
    EDTA plasma (n=4)9790-100
  • 標準曲線:
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/mlOD1OD2AverageCorrected
    20002.408 2.432 2.420 2.279
    10001.659 1.676 1.668 1.527
    5001.042 1.004 1.023 0.882
    2500.660 0.639 0.650 0.509
    1250.429 0.424 0.427 0.286
    62.50.289 0.275 0.282 0.141
    31.250.214 0.229 0.222 0.081
    00.145 0.137 0.141  
  • 數據處理:
  • 貨期:
    3-5 working days

產品評價

靶點詳情

  • 功能:
    Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway. May play a role in the postsynaptic responses of hippocampal neurons.
  • 基因功能參考文獻:
    1. Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PMID: 29879227
    2. On adjusted analysis specifically of the chemotherapy effect in each subgroup, only patients in the presumed Lynch (HR 0.260, 95% CI, 0.09-0.80, P < 0.01) and other BRAF groups (HR 0.45, 95% CI, 0.23-0.87, P < 0.01) had a significant survival benefit from chemotherapy. PMID: 30399198
    3. BRAF V600E is associated with distinct histomorphologic features in nevi. These features may contribute to improving the accuracy of classification and diagnosis of melanocytic neoplasms. PMID: 29653212
    4. Studies have demonstrated that suspicious US features are associated with the BRAFV600E mutation, as well as malignancy in atypia of undetermined significance/follicular lesion of undetermined significance nodules. PMID: 28877096
    5. It was found that RTK inactivation may help to overcome resistance to B-RAF inhibitors via inhibition of tyrosine kinase phosphorylation and a subsequent blocking of the PI3K-AKT-mTOR and MEK-ERK1/2 downstream signaling pathways. The changes eventually mitigated the cell growth and enhanced the Vemurafenib-dependent cell cycle arrest. PMID: 29989578
    6. The pan-RAF inhibitor sorafenib is not affected by expression of BRAF deletion variant. PMID: 29605720
    7. suggests the significance of the BRAFV600E mutation and activation of Wnt signaling pathway in the carcinoma cells PMID: 30223266
    8. Expression of BRAF V600E, RET/PTC, and concomitant expression of BRAF V600E and RET/PTC were significantly associated with patient age and lymph node metastasis (P<0.05).Of the 50 patients with Papillary Thyroid Carcinoma, 37 patients expressed the BRAF V600E gene mutation, eight patients expressed RET/PTC, and five patients showed concomitant BRAF V600E and RET/PTC. PMID: 30254191
    9. This study shows the correlation of blood BRAF(V600E) levels in response to treatment in patients with BRAF(V600E)-positive tumors with all stages of disease. PMID: 29378474
    10. BANCR is downregulated in ccRCC tissues and cell lines, and is associated with ccRCC progression. Thus, BANCR may represent a novel prognostic biomarker and a potential therapeutic target for ccRCC patients PMID: 30200918
    11. Study reports a S6K/PP1alpha/B-Raf pathway that activates MAPK signaling in PI3K/AKT-driven cancers and is opposed by the promyelocytic leukemia (PML) tumor suppressor. Its importance in regulating prostate cancer cell migration and invasion and in metastatic human prostate cancer is demonstrated. PMID: 29335436
    12. novel rearrangement of BRAF present in both infantile fibrosarcoma and cellular congenital mesoblastic nephroma PMID: 29915264
    13. differentially expressed Long Noncoding RNAs correlated with BRAF(V600E) in Papillary Thyroid Cancer. PMID: 28490781
    14. The data are consistent with independent RNAseq data from serial biopsies of melanoma patients treated with BRAF inhibitors. PMID: 29558679
    15. trichostatin A does not alter HDAC transcripts nor BRAF itself, but down-regulates critical components of the MAPK/MEK/BRAF oncogenic pathway, initiating a mitotic arrest. PMID: 30194076
    16. BRAF V600E mutation is associated with increased risk of skin metastases in chemo-resistant metastatic colorectal cancer. PMID: 29380640
    17. BRAF(V600E) gain-of-function mutation has been reported in over 50% of Erdheim-Chester disease patients. PMID: 29556768
    18. Presence of BRAFV600E mutations in melanoma is detecting by immunochemistry using clone VE1. PMID: 29221650
    19. results confirm that BRAF V600E-positive hairy cell leukemia is a relatively rare disorder in the Japanese leukemia patient population. PMID: 30043333
    20. BRAF and EGFR inhibitors are able to synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells PMID: 29534162
    21. A diligent morphological examination to look for the presence of hairy cells along with flow cytometric immunophenotyping showing consistent bright expression of CD200, in addition to well-described characteristic immunophenotype, helps in correctly diagnosing the case. This can be further confirmed by the consistent presence of V600E point mutation in BRAF gene. PMID: 30197362
    22. BRAF mutations are associated with colorectal liver metastases. PMID: 29937183
    23. Multivariate analyses revealed that the PIK3CA mutation and clinical T stage were independent favorable prognostic factors (hazard ratio 0.34, 95% confidence interval: 0.12-0.96, p = 0.042). PIK3CA mutations were significantly associated with APC alterations (p = 0.0007) and BRAF mutations (p = 0.0090). PMID: 30115035
    24. The present findings suggested that miR9 may suppress the viability ofpapillary thyroid carcinoma (PTC) cells and inhibit tumor growth through directly targeting the expression of BRAF in PTC. PMID: 29767243
    25. MET inactivation in the context of the BRAF-activating mutation is driven through a negative feedback loop involving inactivation of PP2A phosphatase, which in turn leads to phosphorylation on MET inhibitory Ser985. PMID: 30224486
    26. Data show that glycogen synthase kinase 3 (GSK3) and proto-oncogene proteins B-raf (BRAF)/MAPK signaling converges to control microphthalmia-associated transcription factor MITF (MITF) nuclear export. PMID: 30150413
    27. these results indicated that STAT3-mediated downexpression of miR-579-3p caused resistance to vemurafenib. Our findings suggest novel approaches to overcome resistance to vemurafenib by combining vemurafenib with STAT3 sliencing or miR-579-3p overexpression. PMID: 30010109
    28. Despite the presence of histological findings indicating long-standing gastroesophageal reflux in 25%, as well as symptomatic gastroesophageal reflux in more than 40%, there was no detectable tissue expression of KRAS or BRAF mutations in adult patients treated for esophageal atresia in childhood. PMID: 28873491
    29. A report of BRAF mutations in acute myeloid leukemias (AML) found mutations only in de novo AML with monocytic differentiation. PMID: 27545333
    30. The occurrence of BRAF V600E mutations in ganglioglioma is common, and their detection may be valuable for the diagnosis and treatment in ganglioglioma. PMID: 30220118
    31. Following adjustment for sex, logistic regression analysis showed that BRAFV600E mutation, transforming growth factor beta (TGF-beta) expression, age, and tumor size are risk factors that can affect tumor clinical stage (p < 0.05). Based on the results of this analysis, we generated a matrix that incorporated 4 variables: patient age, tumor size, BRAFV600E mutation, and TGF-beta expression. PMID: 28892804
    32. Studied frequency of BRAF 1799T>A mutation in Mexican Papillary Thyroid Cancer patients. PMID: 29808165
    33. The frequency of BRAF mutations was significantly higher in Serrated Lesions subgroups with highly methylated epigenotype tumors and microsatellite instability. PMID: 29974407
    34. The rate of EGFR mutation was significantly higher in female and non-smoker patients. In TTF-1 positive cases EGFR mutation was more frequent. Age of the patients over 62-year old was correlated with KRAS mutations. The concordance between ALK IHC and FISH was 58.3%. The MET protein in the cases with MET amplification was 100% positive. PMID: 28756651
    35. Lower CA125 serum levels, negative vascular invasion, and wild-type BRAF status were significantly associated with improved 2-year DFS rates among patient with stage III disease who received adjuvant chemotherapy. PMID: 29562502
    36. genetic association/nutrigenomic studies in population in Seoul, Republic of Korea: Data suggest that (1) relatively low iodine intake and (2) more than excessive iodine intake are significant risk factors for occurrence of BRAF mutations in thyroid gland and may be risk factors for development of PTC (papillary thyroid cancer) in iodine-replete area. PMID: 28258306
    37. The BRAF gene has been reported to be mutated in some human cancers. The BRAF mutations have been implicated in ameloblastoma. PMID: 28650588
    38. The BRAFV600E mutation status may not impact the clinical response to radioiodine therapy for papillary thyroid carcinoma patients PMID: 29762246
    39. Children with Langerhans cell histiocytosis (LCH) tend to have a high overall survival rate and a high incidence rate of BRAF-V600E mutation. PMID: 29658453
    40. BRAF mutations more frequently affected individuals younger than 61 with phototype II. In contrast, NRAS mutations were more frequent in phototype III cases. Mutations of both genes were more frequent in cases with satellitosis in the first melanoma, and in cases with ulceration in the subsequent lesions. PMID: 29180316
    41. Identification of KRAS/NRAS/BRAF mutation status is crucial to predict the therapeutic effect and determine individual therapeutic strategies for patients with colorectal cancer. PMID: 29335867
    42. we did not observe GNAS or BRAF mutations in urachal adenocarcinomas PMID: 28285720
    43. Study finds infrequent BRAF alterations but enriched FGFR alterations in adults as compared with that reported in pediatric pilocytic astrocytomas. In addition, coexistent BRAF and FGFR alterations and a significant association of FGFR alterations with age and tumor location were noted. PMID: 27608415
    44. a low frequency of BRAF or KRAS mutation in Chinese patients with low-grade serous carcinoma of the ovary PMID: 29273082
    45. genetic association studies in population in China: Data suggest that, in patients with unilateral papillary thyroid carcinoma, a mutation in BRAF (V600E) plus multi-focality are both independently and synergically associated with CLNM (central lymph node metastasis) in the population studied. PMID: 29070763
    46. RHEB Y35N expressing cells undergo cancer transformation due to decreased interaction between RHEB and BRAF resulting in overactive RAF/MEK/ERK signaling. Taken together with the previously established function of RHEB to activate mTORC1 signaling, it appears that RHEB performs a dual function; one is to suppress the RAF/MEK/ERK signaling and the other is to activate mTORC1 signaling. PMID: 29320991
    47. The MLH1-93 AA genotype is significantly associated with promoter hypermethylation and MLH1 loss in the context of Sessile serrated adenoma of dysplasia. BRAF mutant microsatellite stable colorectal cancers with the AA genotype most likely arise in traditional serrated adenomas since the A allele does not predispose to methylation in this context. PMID: 29304767
    48. Knowing the mutation status of KRAS, BRAF or PIK3CA in stage II colorectal cancer can significantly improve the accuracy of prognoses. PMID: 28685592
    49. Mutated Liquid-based FNAs BRAF, N/HRAS and TERT mutations were significantly associated with malignancy regardless of the cytological classification PMID: 29094776
    50. our study suggests that an activating BRAF I463T mutation was associated with eosinophilic cystitis. Importantly, analysis of ctDNA obtained through "liquid biopsies" can identify potentially important genomic alterations in patients for whom biopsy may be difficult in terms of risk or cost. PMID: 28829677

    顯示更多

    收起更多

  • 相關疾?。?/div>
    Colorectal cancer (CRC); Lung cancer (LNCR); Familial non-Hodgkin lymphoma (NHL); Cardiofaciocutaneous syndrome 1 (CFC1); Noonan syndrome 7 (NS7); LEOPARD syndrome 3 (LPRD3)
  • 亞細胞定位:
    Nucleus. Cytoplasm. Cell membrane.
  • 蛋白家族:
    Protein kinase superfamily, TKL Ser/Thr protein kinase family, RAF subfamily
  • 組織特異性:
    Brain and testis.
  • 數據庫鏈接:

    HGNC: 1097

    OMIM: 114500

    KEGG: hsa:673

    STRING: 9606.ENSP00000288602

    UniGene: Hs.324250



主站蜘蛛池模板: 亚洲精品无码国产| 成人av片无码免费网站| 亚洲熟女乱综合一区二区在线| 免费国产高清毛不卡片基地| 野花在线无码视频在线播放| 日日碰狠狠添天天爽五月婷| 少妇的肉体aa片免费| 国产精品一线二线三线| 丰满大爆乳波霸奶| 色综合欧美亚洲国产| 国产亚洲日韩一区二区三区| 婷婷色香五月综合激激情| 亚洲日韩va无码中文字幕| 毛片完整版的免费观看| 国产女厕所盗摄老师厕所嘘嘘| 久久久亚洲精品一区二区三区| 无码日韩精品一区二区免费| 免费国产a国产片高清| 蜜桃日本免费观看mv| 日韩精品少妇无码受不了| 欧美老妇人与禽交| 噜噜色综合噜噜色噜噜色| 国产毛片不卡野外视频| 国产av天堂亚洲国产av麻豆| 亚洲午夜久久久影院伊人| 色婷婷久久综合中文久久一本| 久久毛片免费看一区二区三区| 国产精品无码一区二区三级| 午夜成人理论福利片| 亚洲暴爽av天天爽日日碰| 国产成人午夜在线视频a站| 日日噜噜噜噜夜夜爽亚洲精品| 日本丰满少妇xxxx| 成人电线在线播放无码| 久久久国产精品麻豆a片| 日本熟妇大屁股人妻| 日韩在线永久免费播放| 产后漂亮奶水人妻无码| 久久人妻天天av| 久久久www成人免费精品| 男人和女人高潮做爰视频|